VYEPTI® (EPTINEZUMAB-JJMR) PRESCRIBER ORDER FORM							
Fax	completed form, insurance in	formation, and	clinical documentation	n to: (844)	325-	0618	
	Patient Name:				Date of Birth:		
option care health	Address:						
	Phone:	one:		☐ inches ☐	cm	Weight:	☐ lbs ☐ kg
		Clinica	al Information				
Primary Diagnosis Description:					ICD-10 Code:		
Medications previous	sly tried and failed (list medica	on of use):	Has patient received Botox®? ☐ Yes, # of injections ☐ No				
Prescription For existing Vyepti patients: Date of last infusion:							
Vyepti® (Eptinezumab-jjmr) refill as directed x 1 year							
☐ Infuse 100 mg IV over 30 minutes once every 3 months							
☐ Infuse 300 mg IV over 30 minutes once every 3 months							
Using a 50ml NS IV bag, flush IV tubing with NS 10 to 20 mL after each infusion Infuse via a 0.2 micron in-line filter							
Dispense quantity sufficient of Vyepti® 100 mg single dose vials for each dose							
Ancillary Orders							
Anaphylaxis Kit							
☐ Yes Dosage: • Ep • D • N	usion dose, would you like Opt No ninephrine 0.3 mg (> 30 kg), 0.1 phenhydramine 25 mg (> 30 kg) ormal saline 500 mL (> 30 kg) o	.5 mg (15 to 30 k g) or 1.25 mg/kg or 250 mL (≤ 30 k	xg), or 0.01 mg/kg (< 15 (≤ 30 kg) IV or IM; rep	5 kg) SQ or IM eat x 1 in 15 r	1 x 1; re min PR	epeat x 1 in 5 to 15 n N no improvement.	
	RN headache rated > 5 on pain	scale.					
Pre-Medication Orde	rs						
☐ Other: IV Flush Orders							
☐ Peripheral ☐ Implanted ☐ Other:	-						
Lab Orders							
□ No labs ordered at this time.□ Other:							
Nurse will provide on	s and administer and/or teach s going support as needed. Refil	l above ancillary	orders as directed x 1	year.			
I certify that the use of the indicated treatment is medically necessary, and I will be supervising the patient's treatment.							t.
Prescriber Signature:				Date	e:		
Prescriber Name:			per Information Phone:		Fax		
Address:			NPI:		100	•	
City, State: Zip:		Zip:	Office Contact:				

CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that do not require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.